Physician profile
Dawn Webb
NPI 1912612441
$2,782.43
in general payments reported to CMS, 2019-2025
24 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $926 · 2024: $932 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $625.36 | 2023-2025 | Farxiga, Airsupra, Evusheld |
| Lilly USA, LLC | $370.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $283.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $262.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $179.59 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $166.23 | 2023 | Quviviq |
| Shield Therapeutics INC | $159.76 | 2023-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $141.30 | 2023-2025 | Rexulti |
| Pfizer INC. | $104.33 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $62.07 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.95 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $47.07 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $41.00 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.76 | 2023-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $36.75 | 2024-2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.37 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $32.11 | 2024-2025 | Livalo, Zoryve |
| Sanofi-Aventis U.S. LLC | $27.02 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $21.96 | 2025 | |
| Amgen INC. | $19.17 | 2024 | Repatha, Otezla |
| Inogen, INC. | $18.34 | 2023 | Inogen At Home Stationary Concentrator |
| Xeris Pharmaceuticals, INC. | $18.25 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.93 | 2024 | Capvaxive |
| Exact Sciences Corporation | $15.29 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.